Cancer trial to focus on protecting patients from COVID-19 infection

Cancer trial to focus on protecting patients from COVID-19 infection

Cancer trial to focus on protecting patients from COVID-19 infection

OTTAWA — A national clinical trial this summer will focus on protecting cancer patients against severe COVID-19 infection by attempting to boost their compromised immune system.

Researchers from The Ottawa Hospital say they want to explore the potential of IMM-101, a preparation featuring a dead pathogen containing properties that can stimulate the “first-response arm” of the immune system.

Study lead Dr. Rebecca Auer, surgical oncologist and director of cancer research at the Ottawa Hospital, says it could help experts understand why some COVID-19 patients are relatively asymptomatic while others end up in intensive care or die.

“The difference it seems between these two different presentations has to do with how strong your innate, or your sort of non-specific, first-line defence immune system response is to the virus,” Auer said Wednesday.

“And so we’re hoping that by boosting and stimulating this innate immune response, particularly in those vulnerable patients that have a reduced immune response to begin with, we’d be able to prevent symptomatic infections and prevent serious infections.”

Cancer patients are at much higher risk of severe complications from COVID-19 because chemotherapy, cancer surgery and radiation treatments suppress innate immunity even further.

Auer points to an “urgent need” to protect them while the world waits for an effective COVID-19 vaccine, which could take another year or more to develop, test, and implement.

A successful trial could also protect cancer patients against other respiratory infections as well as the coming flu season, says Auer, noting the threat of illness is a fairly big problem for those undergoing treatment.

“A study demonstrated that about 13 to 15 per cent of cancer patients will have to delay or stop their treatment because of influenza during the average flu season,” she says.

“And also cancer patients don’t respond as well to the influenza vaccine every year because their immune system isn’t as strong. So we think that the IMM-101 may in itself be able to help prevent symptomatic influenza infections.”

Auer says IMM-101 has also been tested elsewhere for its anti-cancer properties and that, too, will be examined in this trial, although it’s not the primary objective.

The researchers say the bacteria, Mycobacterium obuense, is safe to use in cancer patients because it has been killed by heat.

The Canadian study will recruit 1,500 patients currently receiving cancer treatment, and participants will be randomly assigned to receive either regular care, or regular care plus IMM-101.

Auer says the treatment would be administered as an injection in the arm, to be followed by two more booster shots.

Researchers will follow patients for a year, watching for any respiratory infections and monitoring whether the treatment works and how long it lasts.

The trials will take place in eight centres located in Ontario, British Columbia and Quebec.

Researchers say people interested in participating should speak with their cancer specialist.

Researchers from the Ottawa Hospital came up with the idea and worked with the Canadian Cancer Trials Group at Queen’s University to design the trial.

Dr. Chris O’Callaghan of the Queen’s University group notes cancer patients are also at greater risk of COVID-19 infection because they require regular medical care, making it difficult to adhere fully to public health guidelines.

“These patients are unable to practice social isolation due to the need to regularly attend hospital to receive critically important cancer treatment,” says O’Callaghan, who will oversee the trial.

Auer says a successful trial of IMM-101 could also suggest usefulness in treating any patient with a reduced innate immune system, such as older patients with chronic illness.

She notes that the tuberculosis vaccine known as BCG — which uses a similar formulation to IMM-101 but uses live bacteria instead of dead bacteria — is being tested around the world to see if it can boost the immunity of health-care workers exposed to COVID-19.

Funding and in-kind support, valued at $2.8 million, comes from the Canadian Cancer Society, BioCanRx, the Ontario Institute for Cancer Research, The Ottawa Hospital Foundation, The Ottawa Hospital Academic Medical Organization, ATGen Canada/NKMax, and Immodulon Therapeutics, the manufacturer of IMM-101.

— By Cassandra Szklarski in Toronto

This report by The Canadian Press was first published July 8, 2020.

The Canadian Press

Cancer

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Alberta’s chief medical officer of health, Dr. Deena Hinshaw, said growing COVID-19 case numbers continue to be a concern in the province. (Chris Schwarz/Government of Alberta)
Alberta announces 1,077 new COVID-19 cases Thursday

There are currently 14,052 active cases in the province

File Photo
Sylvan Lake Town Council asks for a mask bylaw to be brought forward for consideration

The bylaw would require face coverings in all indoor Town-owned and operated facilities

The Sylvan Lake Food Bank with fully stocked shelves. File Photo
Sylvan Lake Food Bank to open for donations in lieu of Stuff-A-Bus

The annual stuff-a-bus event has been postponed until sometime in the new year

Alberta’s chief medical officer of health, Dr. Deena Hinshaw, said the 500 deaths from COVID-19 in the province are a tragic milestone. (Photo by Chris Schwarz/Government of Alberta)
Alberta hits ‘tragic milestone’ with more COVID-19 deaths

Province up to 500 COVID-19 deaths, adds 1,265 cases

Photo Submitted
Sylvan Lake Grade 2 students in Holiday Healing Campaign

Students in Nicole Eleniak’s class worked to share love and joy with other children this holiday

The corporate headquarters of Pfizer Canada are seen in Montreal, Monday, Nov. 9, 2020. The chief medical adviser at Health Canada says Pfizer’s COVID-19 vaccine could be approved in Canada next month. THE CANADIAN PRESS/Ryan Remiorz
Health Canada expects first COVID-19 vaccine to be approved next month

Canada has a purchase deal to buy at least 20 million doses of Pfizer’s vaccine,

People wear face masks as they pose next to a Christmas display in Montreal, Sunday, November 22, 2020, as the COVID-19 pandemic continues in Canada and around the world. THE CANADIAN PRESS/Graham Hughes
How to tell family their Christmas gathering is too risky and you’re not going

Dr. Hurst says it’s best to frame the conversation from a place of care, stressing safety precautions.

A sign instructs people to wear masks in downtown Calgary on Friday, Oct. 30, 2020. Pub and restaurant owners are trying to figure out how to comply with a stricter COVID-19 measure in Alberta that dictates only six people from the same household can sit at one table. THE CANADIAN PRESS/Jeff McIntosh
Brewpub owner pleased Alberta not closing sit-down dining as COVID-19 cases soar

Alberta’s caseload of COVID-19 infections has been growing for weeks

This undated photo issued by the University of Oxford shows of vial of coronavirus vaccine developed by AstraZeneca and Oxford University, in Oxford, England. (University of Oxford/John Cairns via AP)
Canada can make vaccines, just not the ones leading the COVID-19 race

Canada has spent more than $1 billion to pre-order seven different developing COVID-19 vaccines

(File photo)
Alberta woman charged after allegedly hitting boy with watermelon at B.C. campsite

Police say a disagreement among friends at an Adams Lake campsite turned ugly

A pedestrian wears masks while out walking in front of the Alberta Legislature as the COVID-19 numbers spike in Edmonton on Tuesday November 24, 2020. THE CANADIAN PRESS/Jason Franson
Doctor says Alberta restrictions not enough to reduceCOVID-19 strain on hospitals

Mithani notes people are still allowed to gather indoors at large places of worship and in bars,

Prime Minister Justin Trudeau speak to the media about the COVID-19 virus outside Rideau Cottage in Ottawa, Friday, Nov. 20, 2020. THE CANADIAN PRESS/Adrian Wyld
Canada’s inability to manufacture vaccines in-house will delay distribution: Trudeau

First doses of COVID-19 vaccine expected in first few months of 2021, prime minister says

Most Read